内舒拿治疗变应性鼻炎的临床研究

目的:评价糠酸莫米松鼻喷雾剂(商品名:内舒拿)治疗变应性鼻炎的临床疗效及安全性。方法:回顾性分析我院2011年1～10月收治变应性鼻炎160例患者的临床资料,随机分为对照组和实验组。对照组采用曲安奈德鼻喷雾剂,实验组采用糠酸莫米松鼻喷雾剂,观察比较两组的疗效及不良反应。结果:糠酸莫米松鼻喷雾剂临床疗效评价例数为100例,曲安奈德鼻喷雾剂临床疗效评价例数为60例,两药临床有效率分别为88%和80%,药物不良反应发生率分别为10%和13%。结论:糠酸莫米松鼻喷雾剂治疗变应性鼻炎安全、有效。     

抗组胺鼻喷雾剂与糖皮质激素鼻喷雾剂对于常年性变应性鼻炎的疗效

目的比较抗组胺鼻喷雾剂和糖皮质激素鼻喷雾剂对于常年性变应性鼻炎的疗效。方法本实验将92例常年性变应性鼻炎患者随机分为两组,采取双盲、安慰剂干预及交叉设计的方法比较抗组胺鼻喷雾剂与安慰剂和糖皮质激素鼻喷雾剂与安慰剂的疗效。两个实验组都采用Balaam设计随机分为4个亚组,即AA组(药物-药物),PA组(安慰剂-药物),AP组(药物-安慰剂)和PP组(安慰剂-安慰剂)。利用调查日志记录症状变化情况。应用SAS中的PROC MIXED程序对数据进行分析。结果与安慰剂相比较糖皮质激素鼻喷雾剂较抗组胺鼻喷雾剂在缓解除流涕以外的所有症状方面疗效更显著。在调查日志中,与安慰剂相比较糖皮质激素鼻喷雾剂较抗组胺鼻喷雾剂在缓解除白天嗜睡以外的所有症状方面疗效更显著。基于调查日志中的数据,糖皮质激素鼻喷雾剂和抗组胺鼻喷雾剂在改善睡眠如同白天嗜睡和鼻塞方面一样疗效更优。结论糖皮质激素鼻喷雾剂在睡眠、白天嗜睡、打喷嚏、眼部及鼻部搔痒、以及鼻塞等症状上效果优于抗组胺鼻喷雾剂。因此,对于缓解变应性鼻炎症状糖皮质激素鼻喷雾剂比抗组胺鼻喷雾剂等有效。糖皮质激素鼻喷雾剂可以作为常年性变应性鼻炎的一线用药。     

浅谈布地奈德鼻喷雾剂联合超短波治疗过敏性鼻炎的临床观察

目的:观察布地奈德鼻喷雾剂配合超短波治疗过敏性鼻炎的临床疗效。方法:选取2017年3月至2018年2月收治的110例常年性变应性鼻炎患者作为研究对象,将其分为对照组和观察组各55例。观察组采用布地奈德鼻喷雾剂配合超短波治疗,1次/d;对照组仅采用地奈德鼻喷雾剂治疗,对每侧鼻腔喷2喷治疗,治疗4周后评定疗效。结果:观察组治疗总有效率为9818%;对照组治疗总有效率为8727%,两组临床疗效比较差异有统计学意义(P005)。结论:采用布地奈德鼻喷雾剂配合超短波治疗过敏性鼻炎临床疗效确切,疗效明显优于单用布地奈德鼻喷雾剂组。     

布地奈德鼻喷雾剂联合酮替酚治疗儿童变应性鼻炎54例

目的 探讨布地奈德鼻喷雾剂和酮替酚联合应用治疗儿童变应性鼻炎的疗效。方法 将54例儿童变应性鼻炎患者给予布地奈德鼻喷雾剂+酮替酚治疗，分别于治疗前后记分，而后评定疗效，疗程14 d。结果 近期疗效总有效率达92.59%，无明显不良反应。结论 布地奈德鼻喷雾剂联合酮替酚治疗儿童变应性鼻炎安全、有效。     

鼻敏喷雾剂的研制及临床评价

目的：制备一种新的治疗过敏性鼻炎制剂。方法：主要成份为地塞米松，麻黄素，庆大霉素，按照一般制备滴鼻剂方法制备。结果：本品临床疗效确切，无粘膜刺激性且质量稳定。结论：鼻敏喷雾剂可在临床应用。     

曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床研究

目的评价曲安奈德鼻喷雾剂治疗过敏性鼻炎的临床疗效及安全性,方法以丙酸倍氯米松鼻喷雾剂(商品名伯克纳)为对照药,采用开放性、随机对照、多中心临床试验的方法治疗过敏性鼻炎160例.剂量用法曲安奈德鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日1次,每揿55μg;丙酸倍氯米松鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿50μg.疗程均为2周.结果曲安奈德鼻喷雾剂与丙酸倍氯米松鼻喷雾剂临床疗效评价例数分别为100例和60例,两药临床有效率分别为8 8%和90%,药物不良反应发生率分别为13%和10%.以上结果经统计学处理均无显著差异(P＞0.05).结论曲安奈德鼻喷雾剂治疗过敏性鼻炎安全有效.     

伯克纳治疗血管运动性鼻炎的疗效观察

目的:评价丙酸倍氯米松鼻喷雾剂(商品名:伯克纳)治疗血管运动性鼻炎的临床疗效及安全性.方法:以曲安奈德鼻喷雾剂为对照药,采用开放性、随机对照方法治疗血管运动性鼻炎160例,剂量用法:丙酸倍氯米松鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿50μg;曲安奈德鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿55μg...     

治疗过敏性鼻炎在小儿哮喘中的地位

目的 观察在支气管哮喘基础治疗上加用糠酸莫米松鼻喷雾剂对小儿哮喘合并过敏性鼻炎的临床疗效,以评估治疗过敏性鼻炎在小儿哮喘中的地位.方法 89例哮喘患儿随机分成两组,对照组常规用药,实验组加用糠酸莫米松鼻喷雾剂喷鼻治疗,2周后观察疗效.结果 糠酸莫米松鼻喷雾剂实验组症状及肺功能较对照组明显增加,P<0.05,有统计学意义.结论 治疗变应性鼻炎在小儿哮喘中有重要地位,应该联合治疗.     

丙酸氟替卡松联合氯雷他定治疗变应性鼻炎34例

目的：探讨丙酸氟替卡松联合氯雷他定治疗变应性鼻炎的疗效。方法：选择本院收治的68例临床确诊为中重度常年性变应性鼻炎的患者,将其随机分为治疗组和对照组,每组34例,治疗组给予丙酸氟替卡松鼻喷雾剂与氯雷他定片联合治疗,对照组仅予丙酸氟替卡松鼻喷雾剂治疗,观察两组的疗效及副反应发生情况。结果：治疗组总有效率为91.2%,对照组总有效率为79.4%,治疗组疗效优于对照组（P〈0.05）。结论：丙酸氟替卡松鼻喷雾剂联合氯雷他定片治疗中重度常年性变应性鼻炎疗效显著,优于单用丙酸氟替卡松鼻喷雾剂治疗。     

曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效观察

目的观察曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎的临床疗效。方法随机选择门诊就诊的儿童过敏性鼻炎患者76例,每天应用曲安奈德鼻喷雾剂一次,每次各鼻孔一喷(110μg/d),连续使用,最长不超过30d。结果曲安奈德鼻喷雾剂治疗儿童过敏性鼻炎10d有总效率达78.95%,20d有总效率达88.16%,30d总有效率达93.42%;与治疗前后比较,治疗后10d、20d、30d各项症状改善情况有明显变化,统计学指标P<0.01。结论曲安奈德鼻喷雾剂对治疗儿童过敏性鼻炎方面有显著疗效,使用方便,不良反应轻,适于儿科临床应用。     

辛芷鼻敏胶囊对变应性鼻炎实验大鼠血清IL-1和IL-4的影响

目的：观察辛芷鼻敏胶囊对变应性鼻炎（AR）实验大鼠血清IL-1和IL-4表达的影响。方法：卵清蛋白致敏大鼠制作变应性鼻炎大鼠模型。大鼠分成正常组、模型组和辛芷鼻敏胶囊组,术后连续给药10d,测定大鼠血清中IL-1和IL-4水平。结果：与模型组比较,辛芷鼻敏胶囊组显著降低大鼠血清中IL-1和IL-4水平,差异均有统计学意义（P<0.05）。结论：辛芷鼻敏胶囊可以降低IL-1和IL-4水平起到一定的治疗作用。     

鼻敏颗粒的临床前药效学研究

目的 通过临床前研究,评价鼻敏颗粒开发成院内制剂的安全性和有效性.方法 采用最大给药量法进行急性毒性实验,采用二甲苯致小鼠耳肿胀实验评价其抗炎作用,采用甲苯二异氰酸酯(TDI)致过敏性鼻炎豚鼠模型评价其对过敏性鼻炎的治疗作用.结果 急性毒性实验:鼻敏颗粒以86 g生药/kg灌胃给予小鼠,未见明显毒性反应.药效学实验:鼻...     

鼻敏片对寒证变应性鼻炎豚鼠辅助性T细胞17/调节性T细胞平衡的影响

目的:探讨鼻敏片对寒证变应性鼻炎(allergic rhinitis,AR)豚鼠辅助性T细胞17(Th17)/调节性T细胞(Treg)表达水平的影响及其作用机制.方法:将40只雄性豚鼠随机分为空白组、模型组、鼻敏片组和氯雷他定片组,以复方凉药+卵清蛋白致敏法建立寒证AR模型后给予相应的药物干预,治疗15 d后,取血清和...     

抗过敏性鼻炎甘辛喷雾剂的研究

目的研制复方甘草和辛夷(甘辛)鼻用抗过敏喷雾剂。方法以甘草提取物甘草甜素和辛夷花提取液为主药制备成鼻用喷雾剂,建立RP-HPLC测定甘草酸含量,以2.4-二异氰酸甲苯酯(TD I)介导的豚鼠超敏反应为模型,观察甘辛喷雾剂模型对过敏性鼻炎的疗效。结果制剂制备工艺可行,质量稳定,RP-HPLC对甘草酸铵含量测定结果可靠,重现性好;甘辛喷雾剂大小两个剂量组均在一定程度上使鼻黏膜上皮下嗜酸性粒细胞、淋巴细胞、浆细胞和嗜中性粒细胞减少,腺体增生和分泌亢进得到有效的抑制。结论甘辛喷雾剂可有效抑制超敏反应过程,保护鼻黏膜组织结构。     

敏停喷鼻剂对TDI致豚鼠过敏性鼻炎模型的影响

目的研究敏停喷鼻剂对豚鼠过敏性鼻炎模型的影响。方法用TDI致豚鼠过敏性鼻炎造模型，观察敏停喷鼻剂对过敏性鼻炎模型的鼻部过敏症状以及鼻黏膜病理组织形态学的影响。结果敏停喷鼻剂能明显减轻豚鼠过敏性鼻炎模型鼻部过敏症状以及鼻黏膜上皮炎细胞的浸润。结论敏停喷鼻剂对过敏性鼻炎可能具有较好的疗效。     

盐酸氮卓斯汀喷鼻剂与辅舒良在治疗变应性鼻炎中的疗效分析

目的比较盐酸氮卓斯汀喷鼻剂同辅舒良在治疗常年性变应性鼻炎中的疗效。方法在确诊为常年性变应性鼻炎的231例患者,随机分成两组,其中123例患者对其用盐酸氮卓斯汀喷鼻剂进行治疗,另外108例用辅舒良(丙酸氟替卡松鼻喷剂)进行治疗,对比两组的疗效。结果盐酸氮卓斯汀组与辅舒良组治疗效果相当,但盐酸氮卓斯汀起效时间更快。从不良反应看,盐酸氮卓斯汀有个别患者诉有一过性轻微口苦;辅舒良组有10例出现鼻黏膜干燥,有3例出现鼻出血。盐酸氮卓斯汀不良反应更少。结论当常年性变应性鼻炎需要快速、安全和高效减轻症状时盐酸氮卓斯汀喷鼻剂是重要的选择之一。     

Efficacy and safety of montelukast add-on therapy in allergic rhinitis

Allergic rhinitis is a common airways hypersensitivity disease. Histamine and leukotrienes are involved in the pathogenesis of allergic rhinitis. Conventional treatments include topical steroids and antihistamines. Due to the adverse effects of these treatments, new drugs like leukotriene receptor antagonists are being investigated for the treatment of allergic rhinitis. A total of 90 patients suffering from allergic rhinitis were enrolled in this prospective, randomized, controlled study. Patients were divided randomly into three groups of 30 patients each. Group I was administered fluticasone nasal spray (200 μg in each nostril) once a day, Group II was administered fluticasone nasal spray (200 μg in each nostril) plus cetrizine (10 mg) orally once a day and Group III was administered fluticasone nasal spray (200 μg in each nostril) plus montelukast (10 mg) orally once a day. Efficacy was measured based on daytime and nighttime symptom scores. Safety was evaluated on the basis of psychomotor tests, laboratory investigations and subjective assessment. The present study showed that montelukast add-on therapy is as efficacious as conventional therapies in controlling total symptom score, but it is more efficacious in controlling nighttime symptoms. Furthermore, montelukast add-on therapy does not cause psychomotor impairment as observed with cetrizine.     

Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis

STUDY OBJECTIVE: To systematically review the efficacy of azelastine nasal spray for the treatment of allergic rhinitis. DESIGN: Meta-analysis of published randomized controlled trials reported in English. DATA SOURCE: Published literature from the PubMed-MEDLINE database. PATIENTS: Patients aged at least 12 (United States) or 16 years (Europe) with allergic rhinitis or nonallergic vasomotor rhinitis. MEASUREMENTS AND MAIN RESULTS: A global assessment of efficacy was used to estimate the number needed to treat for azelastine nasal spray compared with placebo or active comparators. The total symptom score was used to compare the effect size between azelastine and placebo. In five comparisons of azelastine and placebo, azelastine was most efficacious, with a summary number needed to treat of 5.0 (95% confidence interval [CI] 3.3-10.0). In reviewing 11 studies of azelastine versus active comparators, we found no significant difference between azelastine and active comparators (number needed to treat 66.7, 95% CI 14.3 to infinity to 25). Azelastine was more efficacious than placebo in terms of total symptom score (effect size of 0.36, 95% CI 0.26-0.46). CONCLUSION: Azelastine nasal spray was more efficacious than placebo in the treatment of allergic rhinitis. No significant differences were observed between azelastine and active comparators for the treatment of allergic rhinitis; however, when azelastine was compared with oral antihistamines as monotherapy, the trend favored azelastine. Because azelastine appears to be as efficacious as oral antihistamines, the choice of treatment for seasonal allergic rhinitis should depend on the patient's preference regarding the route of administration, adverse effects, and the cost of the drug.     

Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis

OBJECTIVE: The objective of the study was to evaluate the effectiveness of azelastine (Astelin) nasal spray, a topical second-generation antihistamine, in the treatment of symptoms of seasonal allergic rhinitis, seasonal allergic rhinitis with nonallergic triggers (mixed rhinitis), and nonallergic vasomotor rhinitis. RESEARCH DESIGN AND METHODS: A total of 2343 primary care physicians, allergists, ENT specialists, and other health professionals participated in this 2-week, open-label evaluation of azelastine nasal spray. Data were collected through a physician questionnaire that included patient demographics, rhinitis diagnosis, medication history, and inclusion/exclusion criteria; and two patient questionnaires that included symptom history, response to previous rhinitis medications, symptom control, and level of satisfaction with azelastine nasal spray. A completed physician questionnaire and two completed patient questionnaires were required for each patient to be included in the analysis. Patients who qualified for enrollment were given open-label azelastine nasal spray and instructed to administer 2 sprays per nostril twice daily for 2 weeks. RESULTS: A total of 1225 health professionals enrolled 7864 patients into the study. Completed physician and patient questionnaires were returned by 1081 health professionals and 5073 patients, 4364 of whom used azelastine nasal spray as their only rhinitis medication during the 2-week study period. The patients were predominantly caucasian (82.6%) and female (61.1%), with a mean age of 50 years. The majority had a diagnosis of mixed rhinitis (51.5%), followed by seasonal allergic rhinitis (32.3%), and nonallergic (vasomotor) rhinitis (16.2%). After 2 weeks of treatment, the percentage of patients reporting some control or complete control of individual symptoms ranged from 78% for postnasal drip in patients with nonallergic vasomotor rhinitis to 90% for sneezing in patients with seasonal allergic rhinitis. More than 85% of patients who reported difficulty sleeping or impairment of daytime activities due to rhinitis symptoms had improvement in these parameters. Azelastine nasal spray was well tolerated, the discontinuation rate due to adverse events was 2.3%. CONCLUSIONS: Azelastine nasal spray was reported to control all rhinitis symptoms, including nasal congestion, regardless of rhinitis diagnosis during the 2-week study period. Patients with seasonal allergic rhinitis and patients with seasonal allergic rhinitis plus nonallergic triggers were identified as patient types most likely to respond to azelastine nasal spray.     

曲安奈德鼻喷雾剂治疗变应性鼻炎的疗效观察

目的观察曲安奈德鼻喷雾剂对变应性鼻炎的临床疗效。方法用曲安奈德鼻喷雾剂治疗42例12-60岁常年性变应性鼻炎患者,治疗时间1个月。在治疗前以及治疗后1周、1个月、6个月分别观察记录并评分。结果42例在治疗后1周、1个月、6个月各项观察指标记分均明显降低,分析差异有统计学意义（P均〈0.05）;治疗后1周、1个月、6个月的有效率有统计学差异（P〈0.05）。无1例发生明显的毒副反应。结论曲安奈德鼻喷雾剂是治疗过敏性鼻炎安全、有效的药物。